Estimation of relative biological effectiveness of 225Ac compared to 177Lu during [225Ac]Ac-PSMA and [177Lu]Lu-PSMA radiopharmaceutical therapy using TOPAS/TOPAS-nBio/MEDRAS

Mikhail Rumiantcev,Wei Bo Li,Simon Lindner,Grigory Liubchenko,Sandra Resch,Peter Bartenstein,Sibylle I. Ziegler,Guido Böning,Astrid Delker
DOI: https://doi.org/10.1186/s40658-023-00567-2
2023-09-12
EJNMMI Physics
Abstract:Over recent years, [ 225 Ac]Ac-PSMA and [ 177 Lu]Lu-PSMA radiopharmaceutical therapy have evolved as a promising treatment option for advanced prostate cancer. Especially for alpha particle emitter treatments, there is still a need for improving dosimetry, which requires accurate values of relative biological effectiveness (RBE). To achieve that, consideration of DNA damages in the cell nucleus and knowledge of the energy deposition in the location of the DNA at the nanometer scale are required. Monte Carlo particle track structure simulations provide access to interactions at this level. The aim of this study was to estimate the RBE of 225 Ac compared to 177 Lu. The initial damage distribution after radionuclide decay and the residual damage after DNA repair were considered.
radiology, nuclear medicine & medical imaging
What problem does this paper attempt to address?